As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit (angela.steinbach@uk-koeln.de or vassiliki.dimitriou@uk-koeln.de).

COVID-19_MPI

AcronymISRCTNEudraCTNCT (clinicaltrials.gov)DRKS

The Multidimensional Prognostic Index (MPI) for the Prognostic Stratification of Older Inpatients with Covid-19: A Prospective Observational Trial

Status: Planned (Transit Ethics), pub.

Purpose / Objectives

Primary Outcome

To evaluate if the MPI can predict in Covid-19 older inpatient

  1. the admission to ICU
  2. In-hospital mortality

 

Secondary Outcomes

To assess after 3-months whether the MPI predicts

  1. the length of stay
  2. rehospitalization
  3. admission in long-term care facility
  4. mortality

 

Diagnosis

Patient attributes

Inclusion criteria

  • Patients ≥ 65 years of age
  • Consecutively admitted to the hospital with ascertained diagnosis of COVID-19 through swab with RT-PCR
  • Willing to participate to the study

Exclusion criteria

  • Age < 65 years
  • Unwilling/unable to participate to the study

Trial design

  • Prospective

Intervention

At baseline, after signing informed consent, all recruited patients will undergo data collection for the calculation of the CGA-based MPI including ADL and IADL, SPMSQ, MNA-SF, Exton-Smith score, number of drugs taken, comorbidities and cohabitation status.

 

In addition, discharge destination, therapy plan at admission and discharge, length of hospital stay, main diagnosis and other diagnoses, will be collected. Moreover clinical, biological and radiological parameters regarding COVID-19 infection will be collected at baseline and at hospital discharge.

 

After 3 months from discharge, patients and/or caregivers will be contacted to collect information about survival and rehospitalizations.

 

Documents (password protected)

Responsibilities in overall trial

National Coordinating Investigator

Prof. Dr. Dr. Maria Cristina Polidori Nelles